A healthcare professional draws up a dose of the Oxford/AstraZeneca Covid-19 vaccine at the vaccination centre set up inside Brighton Centre in Brighton, southern England, on January 26, 2021.
Ben Stensall | AFP | Getty Images
LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% against severe disease and hospitalization.
The results were published Monday
It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.
Germany, France, Italy and Spain are among those that have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is safe and effective.
This is a developing story and will be updated shortly.
This article was originally published by Cnbc.com. Read the original article here.